Tick-borne encephalitis vaccination in multiple sclerosis

Abstract

Objective

To assess the changes in disease activity after tick-borne encephalitis (TBE) vaccination in patients with multiple sclerosis (MS) on a variety of disease-modifying drugs and to assess the immunogenicity, safety, and clinical tolerability of the vaccine in this patient group.

Methods

We conducted a prospective, multicenter, nonrandomized observational study. We enrolled 20 patients with MS receiving TBE vaccination who had been on disease-modifying treatment (DMT) for at least 6 months. Serum samples were obtained before and after 4 weeks of vaccination to determine the specific TBE antibody response. MS disease activity (Expanded Disability Status Scale and relapse rates) was evaluated for 1 year after immunization. Local and systemic adverse events were registered.

Results

In 20 subjects with TBE vaccination, the annualized relapse rate decreased from 0.65 in the year before vaccination to 0.21 in the following year. Expanded Disability Status Scale remained stable during the 2-year period before vaccination and 1 year after vaccination (range: 1.50–1.97). The geometric mean titer (GMT) increased from 169 Vienna units per milliliter (VIEU/mL) to 719 VIEU/mL 4 weeks after vaccination (p = 0.001), and 77.8% had protective antibody titers after vaccination. In 9 patients treated with beta interferons, GMT increased from 181 VIEU/mL to 690 VIEU/mL (p = 0.018). Three subjects treated with glatiramer acetate developed a 2- to 9.6-fold increase. Patients treated with fingolimod developed the lowest increase in antibody titer.

Conclusion

TBE vaccination showed good tolerability and was safe in patients with MS. MS disease activity was not increased, and annualized relapse rates decreased after vaccination. Vaccine response differs according to the underlying DMT.

Trial registration

ClinicalTrials.gov, clinicaltrials.gov, Identifier: NCT02275741.

Tick-borne encephalitis (TBE) is an infection of the human CNS caused by the TBE flavivirus (TBEV). It is predominantly transmitted by tick bites and is endemic in Eurasia were 0.1%–5% of ticks harbor TBEV.¹ The TBE attack rate for travelers to endemic areas in Europe is 0.5–1.3 per 100,000 for the exposed at-risk population.² Most infected subjects do not develop clinical symptoms. However, up to 25% of those exposed exhibit CNS involvement—mainly meningitis and meningoencephalitis with a case fatality rate between 0.5% and 2% in Europe.³ Because of the lack of treatment options available, vaccination and tick-bite prevention are eminent strategies in populations at risk.⁴ Reports of potentially detrimental effects on the course of multiple sclerosis (MS) have prompted both patients and their physicians to adopt a more cautious attitude toward the use of vaccines. Immunocompromised patients may mount a lower immune response and also exhibit a more rapid antibody decline after vaccination.⁵ Special consideration must be given to adequate immune protection against vaccine-preventable diseases before and during immunomodulatory therapy of MS.⁶

The aim of this study was to evaluate the safety and immunogenicity of licensed TBE vaccines in MS.

Methods

This prospective, multicenter, nonrandomized observational study at specialized outpatient MS care centers included patients with MS aged between 18 and 70 years who had been on disease-modifying treatment (DMT) for at least 6 months and who had an indication for TBE vaccination. Patients with MS relapse or other disease activity during the previous 6 months were excluded.

All patients who received TBE vaccination on a routine basis were offered to participate in this study. Baseline characteristics were collected along with details of the MS disease. Subjects received a single dose of 1 of the 2 available inactivated TBE vaccines (FSME Immun, TBEV Neudoerfl strain; Encepur, TBEV K23 strain) in the deltoid muscle in an open-label manner.

Serum samples were obtained before and 4 weeks after vaccination. Serology for the TBE immunoglobulin G-antibody response was performed in duplicate using an enzyme immunoassay (FSME immunoglobulin G ELISA; IBL International, Hamburg, Germany) according to the manufacturer's protocol. Titers were expressed in Vienna units per milliliter (VIEU/mL) and rated according to the manufacturer's protocol: <63 VIEU/mL negative, 63–126 VIEU/mL borderline, and >126 VIEU/mL positive.

Subjects had follow-up visits after 1, 3, 6, and 12 months. Local and systemic adverse events (AEs) were registered after 1 month.

Safety and immunogenicity were analyzed in the intention-to-treat population. Samples below the cutoff titer were set to 25 VIEU/mL for statistical analysis.

All statistical analyses were performed using Prism 5 (5.04, GraphPad Software Inc.). Values were expressed as mean ± SD. Mann-Whitney U test was used to compare annualized relapse rates. Where otherwise appropriate, the Wilcoxon rank test was used. All reported p values are 2 sided; values of 0.05 or less were considered to indicate statistical significance.

Standard protocol approvals, registrations, and patient consents

The study was approved by the local ethics committee (Rostock HV 2010-0002) and registered at ClinicalTrials.gov (NCT02275741). The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki.

Data availability

Anonymized data on individual patient level will be shared by request from any qualified investigator.

Results

In total, 20 patients with MS aged between 25 and 65 years received the TBE vaccine and were included in this study (table).

Table.

Characteristics of the enrolled subjects

The annualized relapse rate was 0.5 two years before vaccination and 0.65 in the year before vaccination. After vaccination, 3 relapses occurred: (1) 62 days after vaccination, (2) between month 4 and 6, and (3) between month 7 and 12, resulting in a reduction of the annualized relapse rate to 0.2143 (p = 0.0459) (figure 1A). Mean Expanded Disability Status Scale (EDSS) remained stable during the 2-year period before vaccination and 1-year period after vaccination. The mean EDSS at vaccination was 1.88, and there was a nonsignificant decrease in (1.62 and 1.50) 3 and 6 months after vaccination (figure 1B).

Figure 1. Annualized relapse rates (A) and mean EDSS (B).

*p = 0.0459 (year −1 vs year +1). (A) Annualized relapse rates during the 2-year period before and 1-year period after TBE vaccination. (B) Mean EDSS during the 2-year period before and the 1-year period after TBE vaccination. EDSS = Extended Disability Status Scale; TBE = tick-borne encephalitis.

Four of 20 subjects reported local side effects (pain, induration); none reported systemic AEs during the 4 weeks after vaccination. No additional autoimmune disease was registered during the 1-year of follow-up.

Prevaccination and postvaccination serum samples were available for 18 of 20 subjects. Four of these subjects received a covaccination against tetanus/diphtheria and 2 others received a covaccination against seasonal influenza at the time of TBE vaccination.

Geometric mean titers (GMTs) in these 18 patients increased from 169 to 719 VIEU/mL 4 weeks after vaccination (p = 0.001), and 14/18 (77.8%) developed protective antibody titers.

Among the subjects without detectable antibody titers before vaccination (4/18 subjects), only 1 developed detectable, though not protective, antibody titers. In those 14 subjects with detectable antibody titers before vaccination, GMT increased from 732 to 3,416 VIEU/mL (p = 0.001) (figure 2). Among 9 patients treated with beta interferons, GMT increased from 181 VIEU/mL to 690 VIEU/mL (p = 0.018). Two patients treated with interferon beta-1a i.m. for 6 months (38-year-old man, EDSS 1.0) and 112 months (46-year-old woman, EDSS 2.0) showed no antibody response. Another patient treated with interferon beta-1a i.m. developed a 2-fold antibody titer increase after TBE vaccination.

Figure 2. TBE antibody titers.

TBE titers before and after 28 days vaccination. Subjects are grouped according to underlying MS therapy (color coding: interferon beta: blue, glatiramer acetate: green, fingolimod: gray, natalizumab: red, cyclic glucocorticosteroids [GCS] pulse: orange). TBE = tick-borne encephalitis; VIEU/mL = Vienna units per milliliter.

Three of 5 subjects treated with glatiramer acetate had protective titers before vaccination and developed a 2-, 3.6-, and 9.6-fold increase, respectively. Two other patients with glatiramer acetate treatment developed insignificant antibody titers and both were vaccinated with TBE and another vaccination (influenza or tetanus/diphtheria).

Two patients treated with fingolimod developed the lowest antibody increase compared with other treatment groups (1.76- and 1.59-fold, respectively).

Discussion

The use of TBE vaccination may be influenced by concerns of vaccination-associated induction or deterioration of MS. Data on patients with MS in the context of TBE vaccination are scarce. One randomized controlled trial showed no increase in MRI activity in 15 patients with MS 6 weeks after TBE vaccination.⁷ In our cohort, no altered clinical disease activity was detected after vaccination. Annualized relapse rates decreased and relapses were rare. The first relapse occurred 62 days after vaccination, making a relationship to the vaccine unlikely.

The long-held concerns that some vaccines might induce autoimmune diseases or lead to an aggravation of existing autoimmune diseases such as MS are unfounded.^8,9 In our cohort, neither neurologic complications nor autoimmune diseases nor other systemic AEs were reported during the follow-up. Although reporting or recall biases cannot be excluded, overall AEs were low. In healthy vaccinees, seroconversion after vaccination is reported in 92%–100%.⁴ All subjects with protective antibody titers mounted an adequate immune response irrespective of the underlying DMT are studied.

The 2 subjects on fingolimod treatment had a low TBE antibody increase as compared to subjects treated with other DMT. However, because of the small number of patients, conclusions regarding responses in patients on individual DMT must be viewed cautiously.

A comparably low antibody response in fingolimod treatment was described after influenza vaccination.¹⁰ In 6 of 18 subjects, TBE was given simultaneously with other vaccines (influenza, tetanus/diphtheria). Notably, 3 of 4 subjects who did not respond to the TBE vaccine received a covaccination. However, interference between vaccines given simultaneously has not yet been adequately evaluated.

Overall, patients developed a 4.26-fold GMT increase. However, 4 subjects did not respond to TBE vaccination. TBE antibody response monitoring might be advisable in patients with DMT. A drawback of this study is its small sample size without randomization. A correlation between clinical disease activity and MRI may have been desirable; however, this study was performed under routine clinical care and routine cerebral imaging is not the standard of care in asymptomatic patients. In addition, the intrascanner and interscanner variability of MRI would have likely led to inconsistent results in this multicenter setting. We therefore focused on clinical findings. Moreover, neither classic immunosuppressive treatments, nor dimethyl fumarate or teriflunomide, nor recently licensed monoclonal antibody therapies (e.g., ocrelizumab or alemtuzumab) against MS were represented in our cohort. However, real-world clinical data on MS activity for relatively long periods of prevaccination and postvaccination were taken into account. In conclusion, this pilot study and available literature make it likely that TBE vaccine is safe in patients with MS. However, MS treatment with recently licensed drugs, not covered in this study, need further investigation.

Glossary

AE

adverse event

DMT

disease-modifying treatment

EDSS

Expanded Disability Status Scale

GMT

geometric mean titer

TBE

tick-borne encephalitis

TBEV

TBE flavivirus

VIEU/mL

Vienna units per milliliter

Appendix. Authors

Study funding

No targeted funding.

Disclosure

A. Winkelmann reports personal compensation from Bayer Healthcare, Celgene, Merck, Novartis, Sanofi Genzyme, and Teva. C. Metze reports no disclosures. S. Frimmel reports research support from Pfizer. E.C. Reisinger reports research support from Cempra, Gilead, GSK, Janssen, Novartis Vaccines, Pfizer, Schering, Seqirus, Themis Bioscience, Valneva and Vectura. U.K. Zettl received speaking fees and travel support for research activities from Alexion, Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva as well as EU, BMBF, BMWi, and DFG. M. Loebermann reports personal compensation from Gilead, Janssen, Pfizer and Sanofi and research support from Cempra, Correvio, Pfizer, Sanofi, Schering, Seqirus, Themis Bioscience, Valneva and Vectura. Go to Neurology.org/NN for full disclosures.